The Efficacy of Using Patient-Derived Organoids to Predict Treatment Response in Colorectal Cancer
- PMID: 36765763
- PMCID: PMC9913532
- DOI: 10.3390/cancers15030805
The Efficacy of Using Patient-Derived Organoids to Predict Treatment Response in Colorectal Cancer
Abstract
Colorectal cancer is an important cause of morbidity and mortality worldwide. The current treatment landscape includes chemotherapy, targeted therapy, immunotherapy, radiotherapy, and surgery. A key challenge to improving patient outcomes is the significant inter-patient heterogeneity in treatment response. Tumour organoids derived from the patients' tumours via surgically resected or endoscopically biopsied tissue, have emerged as promising models for personalised medicine. This review synthesises the findings, to date, of studies which have explored the efficacy of ex vivo organoid sensitivity testing for predicting treatment response. Most studies have focused on predicting the response to standard-of-care radiotherapy and chemotherapy options. There is strong evidence to support organoid sensitivity testing of ionising radiation, 5-fluorouracil, and irinotecan, and to a lesser extent, oxaliplatin and TAS-102. Fewer studies have used organoids to identify patients who are likely to benefit from novel treatment options that otherwise remain in clinical trials. This review also summarises recent advancements in organoid culture to include non-epithelial components of the tumour microenvironment, to allow testing of immunotherapy and certain targeted therapy options. Overall, further prospective trials will support the implementation of organoid-based personalised medicine for colorectal cancer patients in the future.
Keywords: colorectal cancer; organoids; personalised medicine.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- Argilés G., Tabernero J., Labianca R., Hochhauser D., Salazar R., Iveson T., Laurent-Puig P., Quirke P., Yoshino T., Taieb J., et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2020;31:1291–1305. doi: 10.1016/j.annonc.2020.06.022. - DOI - PubMed
-
- Wo J.Y., Anker C.J., Ashman J.B., Bhadkamkar N.A., Bradfield L., Chang D.T., Dorth J., Garcia-Aguilar J., Goff D., Jacqmin D., et al. Radiation Therapy for Rectal Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Pract. Radiat. Oncol. 2021;11:13–25. doi: 10.1016/j.prro.2020.08.004. - DOI - PubMed
-
- Cervantes A., Adam R., Roselló S., Arnold D., Normanno N., Taïeb J., Seligmann J., De Baere T., Osterlund P., Yoshino T., et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2022;34:10–32. doi: 10.1016/j.annonc.2022.10.003. - DOI - PubMed
-
- Van Cutsem E., Cervantes A., Adam R., Sobrero A., Van Krieken J.H., Aderka D., Aguilar E.A., Bardelli A., Benson A., Bodoky G., et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 2016;27:1386–1422. doi: 10.1093/annonc/mdw235. - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
